Foot Reflexology Can Increase Vagal Modulation, Decrease Sympathetic Modulation, and Lower Blood Pressure in Healthy Subjects and Patients With Coronary Artery Disease

Abstract

Complementary and alternative medicine (CAM) has long been used by people to postpone the aging process and to reverse disease progression. Reflexology is a CAM method that involves massage to reflex areas in the feet and hands. This study investigated the effect of foot reflexology (FR) on the autonomic nervous modulation in patients with coronary artery disease (CAD) by using heart rate variability analysis.
Seventeen people with angiographically patent coronary arteries and 20 patients with CAD scheduled for coronary artery bypass graft surgery were recruited as the control and CAD groups, respectively. The normalized high-frequency power (nHFP) was used as the index of vagal modulation and the normalized very low-frequency power (nVLFP) as the index of vagal withdrawal and renin-angiotensin modulation.
In both control and CAD groups, the nHFP was increased significantly whereas the nVLFP was decreased significantly 30 and 60 minutes after FR, as compared with those before FR. The systolic, diastolic, mean arterial, and pulse pressures were significantly decreased after FR in both groups of participants. In the CAD group, the percentage change in heart rate 30 and 60 minutes after FR was smaller than that in the control, and the percentage change in nVLFP 60 minutes after FR was smaller than that in the control. In conclusion, a higher vagal modulation, lower sympathetic modulation, and lower blood pressure can be observed following 60 minutes of FR in both controls and CAD patients. The magnitude of change in the autonomic nervous modulation in CAD patients was slightly smaller than that in the controls.
FR may be used as an efficient adjunct to the therapeutic regimen to increase the vagal modulation and decrease blood pressure in both healthy people and CAD patients.

Full text

8 ALTERNATIVE THERAPIES, jul/aug 2011, VOL. 17, NO. 4 Foot Reexology in Coronary Artery Disease
Wan-An Lu, MD, PhD, is an assistant professor in the Institute
of Cultural Asset and Reinvention, Fo-Guang University, Ilan,
Taiwan. Gau-Yang Chen, MD, PhD, is an associate professor in
the Institute of Biomedical Engineering, National Yang-Ming
University, Taipei, Taiwan. Cheng-Deng Kuo, MD, PhD, is the
principal investigator in the Biophysics Laboratory in the
Department of Research and Education, Taipei Veterans
General Hospital, Taipei, Taiwan.
Corresponding author: Cheng-Deng Kuo, MD, PhD
E-mail address: cdkuo@vghtpe.gov.tw
Age-related changes in autonomic nervous system
control of the circulation are a key feature of age-
associated cardiovascular disease.1,2 Vagal modula-
tion was found to be decre ased in vari ous
physiological and pathological conditions, such as
aging,3 acute myocardial infarction,4 diabetes mellitus,5 chronic
renal failure,6 congestive heart failure,7 and coronary artery disease
(CAD).8-12 In addition, the reduction in cardiac vagal modulation, as
evaluated by spectral heart rate variability (HRV) analysis, correlat-
ed with angiographic severity, independent of previous myocardial
infarction, location of diseased coronary arteries, and left ventricu-
lar function.12 Vagal stimulation has been shown to have an antiar-
rhythmic effect in animal models of acute ischemia13 ,14 and can
terminate ventricular tachycardia in humans.15 A pharmacological
method of using transdermal scopolamine as a cardiac vagal
enhancer was tried in patients with acute myocardial infarction16-19
and congestive heart failure20 and proved to be effective in improv-
ing the autonomic indices that are associated with high mortality.
However, the safety, tolerability, and efcacy of long-term transder-
mal scopolamine treatment remain to be claried.21
Complementary and alternative medicine (CAM) has long been
used to postpone the aging process and to reverse disease progres-
sion. CAM therapies have lasted because in some cases they work as
well as or better than allopathic medicine. With growing public inter-
est in CAM, it is important for medical professionals to examine the
effectiveness of CAM techniques. Among many therapeutic modali-
ties, reexology is often used as an antiaging CAM technique.22
Reexology is a form of complementary medicine that involves
using massage to reex areas in the feet and the hands.23-26 By stimu-
lating and applying pressure to certain areas, one can increase blood
ORIGINAL RESEARCH
Foot Reexology Can Increase Vagal Modulation,
Decrease Sympathetic Modulation, and Lower Blood
Pressure in Healthy Subjects and Patients With
Coronary Artery Disease
Wan-An Lu, MD, PhD; Gau-Yang Chen, MD, PhD; Cheng-Deng Kuo, MD, PhD
Objective • Complementary and alternative medicine (CAM)
has long been used by people to postpone the aging process and
to reverse disease progression. Reexology is a CAM method
that involves massage to reex areas in the feet and hands. This
study investigated the effect of foot reexology (FR) on the
autonomic nervous modulation in patients with coronary
artery disease (CAD) by using heart rate variability analysis.
Study Methods • Seventeen people with angiographically patent
coronary arteries and 20 patients with CAD scheduled for coro-
nary artery bypass graft surgery were recruited as the control and
CAD groups, respectively. The normalized high-frequency power
(nHFP) was used as the index of vagal modulation and the nor-
malized very low-frequency power (nVLFP) as the index of vagal
withdrawal and renin-angiotensin modulation.
Results • In both control and CAD groups, the nHFP was
increased signicantly whereas the nVLFP was decreased sig-
nicantly 30 and 60 minutes after FR, as compared with those
before FR. The systolic, diastolic, mean arterial, and pulse pres-
sures were signicantly decreased after FR in both groups of
participants. In the CAD group, the percentage change in heart
rate 30 and 60 minutes after FR was smaller than that in the
control, and the percentage change in nVLFP 60 minutes after
FR was smaller than that in the control. In conclusion, a higher
vagal modulation, lower sympathetic modulation, and lower
blood pressure can be observed following 60 minutes of FR in
both controls and CAD patients. The magnitude of change in
the autonomic nervous modulation in CAD patients was slight-
ly smaller than that in the controls.
Conclusion • FR may be used as an efcient adjunct to the
therapeutic regimen to increase the vagal modulation and
decrease blood pressure in both healthy people and CAD
patients. (Altern Ther Health Med. 2011;17(4):8-14.)
This article is protected by copyright. To share or copy this article, please visit copyright.com. Use ISSN#10786791. To subscribe, visit alternative-therapies.com.

ALTERNATIVE THERAPIES, jul/aug 2011, VOL. 17, NO. 4 9
Foot Reexology in Coronary Artery Disease
circulation and promote specic bodily and muscular functions. It
has been estimated that more than 20 million Americans have seen
reports of the effectiveness of reexology on television and have read
about this natural technique of healing in national magazines and
newspapers.23 Several books have been written to propagate the reju-
venation effects of reexology.24-26 Though Wang et al27 reviewed ve
studies of reexology in the literature and concluded that there is no
evidence for any specic effect of reexology in any conditions with
the exception of urinary symptoms associated with multiple sclerosis,
others have shown signicant effects using reexology. The feet are
the most common areas treated with reexology.24 Sudmeier et al28
showed that foot reexology (FR) is effective in changing renal blood
flow. Stephenson et al29,30 have shown that FR can relieve pain in
patients with metastatic cancer and decrease anxiety in patients with
breast and lung cancer. Ergonomically created footwear also has been
invented to provide relaxation, reduce swelling, induce blood ow,
and rejuvenate the muscles and nerves in the ankle and foot area.31
Since patients with anxiety or pain are expected to have an ele-
vated sympathetic and a depressed vagal modulation,32,33 it is possi-
ble that treatment with FR can lower sympathetic modulation and
raise vagal modulation. It is therefore worthy of investigating wheth-
er FR can have an effect on the autonomic nervous modulation in
normal controls and in patients with CAD.
MATERIALS AND METHODS
Study Participants
Coronary arteriography was performed in patients with angina
pectoris, unstable angina, previous myocardial infarction, or other
evidence of myocardial ischemia. A panel of cardiologists interpreted
the angiograms. The coronary arteries and branches were divided
into 15 segments according to the Ad Hoc Committee for Grading of
Coronary Artery Disease of the American Heart Association.34 Only
the luminal narrowing in the following segments was used in the
nal assessment: segment 1-3 for the right coronary artery, segments
6 and 7 for the left anterior descending branch, segments 11 and 12
for the circumex branch, and segment 5 for the left main coronary
artery. By conning the analysis to these segments alone, only those
patients who had signicant obstruction in the main epicardial coro-
nary arteries were included in this study. Stenosis was considered to
be signicant if a luminal narrowing >50% was present. Patients
without stenosis or with luminal narrowing <30% were classied as
the control group. Coronary artery bypass graft surgery was suggest-
ed for patients who refused percutaneous coronary intervention or
whose lesions were not suitable for it. Patients with CAD preparing
for coronary artery bypass graft surgery were recruited as the study
group. Patients with angiographically patent coronary arteries were
recruited as the control group. Hypertension was dened as systolic
blood pressure >140 mmHg or diastolic blood pressure >90 mmHg.35
Hyperlipidemia was dened as total cholesterol >200 mg/dL or low
density lipoprotein cholesterol >100 mg/dL.36 Patients who had atri-
al brillation or coexisting valvular heart disease or were using class I
antiarrhythmic medication were excluded from this study. All par-
ticipants were requested to refrain from alcohol or caffeine ingestion
24 hours before the study. The hospital Institutional Review Board
approved this study. The procedure was fully explained to the partic-
ipants, and written informed consent was obtained from them
before the study.
Equipment
The electrocardiogram (ECG) signals were recorded using a
multichannel recorder (Biopac MP150 with 16 channels, MP150CE/
UIM100C/ECG100C, BIOPAC Systems, Inc, Goleta, California) from
conventional lead II, and blood pressure was measured by using a
sphygmomanometer (Kenlu-model K-300 Sphygmomanometer, Di
Tai Precision Ent Co Ltd, Kaohsiung City, Taiwan) on each partici-
pant lying in a supine position. The analog signals of ECG were
transformed to digital signals by using an analog-to-digital converter
with a sampling rate of 400 Hz. Systolic blood pressure (SBP), dia-
stolic blood pressure (DBP), mean arterial blood pressure (MABP),
and pulse pressure (PP) were obtained from each participant before
FR using the sphygmomanometer.
Study Protocol
Before FR, each participant rested in a supine position for 5
minutes, and then 10 minutes of continuous ECG signals and blood
pressure data were recorded. After baseline ECG recording and
blood pressure measurement, the participant received FR for 60
minutes. The ECG recording and blood pressure measurements
were repeated 30 and 60 minutes after FR. All procedures were per-
formed in a bright and quiet room with a room temperature of 24 oC
to 25oC and humidity of 54% to 55%.
FR was performed on participants lying in a comfortable
supine position by a certified foot reflexologist from the Taiwan
Association of Reexology using the techniques of Father Josef ’s
FR.37 The reexologist used the thumb and ngers to apply pressure
to stimulate all reex zones in both feet, which correspond to all
organs, glands, and body parts. The technique of the thumb and n-
gers resembles a caterpillar-like action in reexology.38 Grapeseed oil
is used during FR to prevent friction and possible discomfort because
it is nonsticky and odorless and absorbs easily into the skin.39,40
Heart Rate Variability Analysis
R-wave–detecting software written with the help of Matlab R13
software (MathWorks Inc, Natick, Massachusetts) was used to iden-
tify the peaks of the R waves in the recorded ECG signals. The RR
intervals (the time intervals between two consecutive R waves in the
electrocardiogram, RRI) were then calculated after eliminating ecto-
pic beats. If the percentage of ectopic beats was greater than 5%, then
the participant was excluded from analysis. The last 512 stationary
RRI were used for HRV analysis.
The mean, standard deviation (SDRR) and coefcient of varia-
tion (CVRR) of the 512 stationary RRI were calculated using a stan-
dard formula for each participant. The power spectra of RRI were
obtained by means of fast Fourier transformation (Mathcad,
Mathsoft Inc, Cambridge, Massachusetts). Direct current compo-
nent was excluded before the calculation of the powers. The area
under the curve of the spectral peaks within the range of 0.01-0.4 Hz,
0.01-0.04 Hz, 0.04-0.15 Hz, and 0.15-0.40 Hz were dened as the

10 ALTERNATIVE THERAPIES, jul/aug 2011, VOL. 17, NO. 4 Foot Reexology in Coronary Artery Disease
total power (TP), very low–frequency power (VLFP), low-frequency
power (LFP), and high-frequency power (HFP), respectively.
The Task Force of the European Society of Cardiology and the
North American Society of Pacing Electrophysiology have suggested
that the power within the frequency range of 0.04-0.4 Hz be used for
the normalization of LFP and HFP.41 Since this frequency range cov-
ers only the frequency ranges of LFP and HFP but not VLFP, it may
not be suitable for the normalization of VLFP. Therefore, we used
the power within the frequency range of 0.01-0.4 Hz, which covers
the frequency ranges of VLFP, LFP, and HFP, to normalize VLFP,
LFP, and HFP in this study. The normalized very low-frequency
power (nVLFP
=
VLFP/TP) was then used as the index of vagal with-
drawal, renin-angiotensin modulation, and thermoregulation42-44; the
normalized low-frequency power (nLFP
=
LFP/TP) was used as the
index of combined sympathetic and vagal modulation45; the normal-
ized high-frequency power (nHFP
=
HFP/TP) was used as the index
of vagal modulation; and the low-/high-frequency power ratio (LFP/
HFP) was used as the index of sympathovagal balance.46
Statistical Analysis
Values of HRV and blood pressure measures were presented as
median (25 percentile
-75 percentile). Friedman repeated measures
analysis of variance on ranks (SigmaStat statistical software, Jandel
Scientic, San Rafael, California) was employed to compare the HRV
and blood pressure measures among before FR, 30 minutes after FR,
and 60 minutes after FR. Signicant difference was further analyzed
by pairwise comparison using the Student Newman–Keuls test. The
Mann-Whitney rank sum test was employed to compare the HRV
and blood pressure measures between CAD patients and controls.
To correct for baseline differences on the comparison of HRV
and blood pressure measures between CAD patients and controls,
the percentage changes in HRV and blood pressure measures in each
participant 30 and 60 minutes after FR were calculated using the fol-
lowing formulas:
%C30 = [(C30 min -Cbefore)/(Cbefore)]×100
%C60 = [(C60 min -Cbefore)/(Cbefore)]×100,
where X represents the variable to be compared. The Mann-Whitney
rank sum test was used to compare %C30 and %C60 between con-
trols and patients with CAD. Wilcoxon signed rank test was
employed to compare %C30 with %C60 in both controls and
patients with CAD. A P
<
.05 was considered statistically signicant.
RESULTS
General Characteristics
The percentage of deletion of ectopic beats due to atrial or ven-
tricular arrhythmia was >5% in two patients in the CAD group and
three participants in the control group. Thus, only 20 out of 22
patients in the CAD group and 17 out of 20 patients in the control
group were included in the nal statistical analysis. Table 1 shows
the baseline characteristics of the control and CAD groups. There
were 17 men and 3 women (between 52.5 and 66.0 years of age with
an average of 62.0 years) in the CAD group and 15 men and 2
women (between 52.0 and 66.0 years of age with an average of 56.0
years) in the control group.
Effect of Foot Reexology on Blood Pressure
Table 2 shows the sequential changes in blood pressures after
FR in both groups of participants. The SBP, DBP, and MABP
decreased signicantly after FR in both groups. The PP decreased 30
minutes after FR in both groups and elevated to pre-FR level 60 min-
utes after FR in the control group.
Table 3 shows the percentage changes in blood pressures after
RF in both groups of participants. In the control group, the percent-
age decrease in SBP and PP 30 minutes after FR was larger than that
60 minutes after FR. In the CAD group, the percentage decrease in
PP 30 minutes after FR was larger than that of 60 minutes after FR.
No signicant difference in the percentage change in blood pressures
after FR was found between the two groups.
Effect of Foot Reexology on Heart Rate Variability
Table 4 shows the effects of FR on the time and frequency
domain HRV measures in patients with CAD and control group.
TABLE 1 Baseline Characteristics of the Control and Coronary
Artery Disease (CAD) Groups*
Control Group (n = 17) CAD Group (n = 20) P value
Age (y) 56.0 (52.0-66.0) 62.0 (52.5-66.0) NS
Gender (M/F) 15/2 17/3 NS
Body height (cm) 161.0 (156.0-164.3) 163.5 (157.0-173.0) NS
Body weight (kg) 59.0 (51.5-70.3) 64.0 (58.3-74.5) NS
BMI (m2/kg) 22.2 (21.1-25.0) 24.1 (22.2-26.4) NS
History
Previous MI 0 4 NA
Hypertension 12 15 NS
Diabetes mellitus 6 7 NS
Hyperlipidemia 6 7 NS
Current smoker 7 11 NS
Medication
Beta-blocker 10 15 NS
Calcium antagonist 11 17 NS
Nitrates 13 19 NS
ACE inhibitor 6 10 NS
ARB 1 3 NS
Digitalis 1 1 NS
Aspirin 12 18 NS
Clopidogrel 5 10 NS
Ticlopidine 2 4 NS
Clinical status
One-vessel disease 0 8 NA
Two-vessel disease 0 8 NA
Three-vessel disease 0 4 NA
Left main disease 0 5 NA
Left ventrical aneurysm 0 4 NA
*Values are numbers of patients or medians (25-75 percentile).
Abbreviations: BMI, body mass index; ACE, angiotensin-converting enzyme;
ARB, angiotensin receptor blocker; MI, myocardial infarction; NS, not signi-
cant (P > .05); NA, not assessed.

ALTERNATIVE THERAPIES, jul/aug 2011, VOL. 17, NO. 4 11
Foot Reexology in Coronary Artery Disease
Thirty and 60 minutes after RF, the nHFP was signicantly increased,
whereas the nVLFP was signicantly decreased in both groups of
participants s as compared with those before RF. The VLFP and TP
after FR were signicantly decreased in the control group. The mean
RRI was signicantly increased, and the heart rate was signicantly
decreased after RF in CAD patients. Although the SDRR, TP, VLFP,
LFP, and HFP of the CAD patients before FR were not signicantly
different from those of the controls, they were signicantly larger
than those of the controls 60 minutes after FR. However, the relative
HRV measures including nVLFP, nLFP, nHFP and LFP/HFP were
not signicantly different between the controls and the CAD patients
both before FR and 60 minutes after FR.
Table 5 shows the percentage changes in HRV measures after RF
in both groups of participants. The percentage decrease in SDRR, TP,
VLFP, and LFP and the percentage increase in heart rate 60 minutes
after FR were larger than those of 30 minutes after FR in controls.
There were no signicant differences in the percentage changes in all
HRV measures between 30 minutes and 60 minutes after FR in the
CAD patients.
The percentage increase in mean RRI 30 minutes after FR in the
CAD group was larger than that in the control group, whereas the per-
centage decrease in heart rate 30 minutes after FR in the CAD group
was smaller than that in the control group. Similarly, the percentage
increase in mean RRI, SDRR, TP, VLFP, LFP, and HFP in the CAD
group 60 minutes after FR was larger than those in the control group,
whereas the percentage decrease in heart rate and nLFP in the CAD
group 60 minutes after FR was smaller than those in the control group.
Effect of Beta-blockers on Heart Rate Variability
Table 6 shows that there were no signicant differences in all
HRV measures between participants using or not using beta-block-
ers in either control or CAD group and between the control and
CAD groups whether they were using beta-blockers or not. There are
no differences in the effects of FR on patients whether they were
using or not using beta-blocker medication.
DISCUSSION
Ludwig has defined aging as a time-dependent, irreversible
shift from environmental to intrinsic causation of disease.47 This
intrinsic pathogenesis has two components: the rst one is genetic
and beyond the reach of contemporary health care and the second
one entails the growing number of degenerative lesions due to viral
agents as well as carcinogenesis. Bonnemeier et al have shown that
normal aging is associated with a constant decline of cardiac vagal
modulation due to a signicant decrease of nocturnal parasympa-
thetic activity.48 It has also been shown that depressed vagal modula-
tion is associated increased risk of sudden death in patients with
CAD, and the experimental evidence also suggests a causal
relationship.49-52 With the adverse prognostic implication of reduced
cardiac vagal activity in its susceptibility to life-threatening
arrhythmia,51-53 any intervention that can enhance the vagal modula-
tion will be benecial to patients, especially for those at high risk for
life-threatening arrhythmia. Exercise and medication have been found
to increase the vagal modulation of the study participants,16-20,53-55,
TABLE 2 Effect of Foot Reexology (FR) on Blood Pressure*
Before FR 30 Min After FR 60 Min After FR
Control group (n = 17)
SBP (mmHg) 136.0 (129.8-141.8) 115.0 (109.8-123.3)‡ 124.0 (114.0-133.5)‡§
DBP (mmHg) 75.0 (72.8-80.3) 67.0 (63.0-73.3)‡ 67.0 (62.8-75.0)‡
MABP (mmHg) 95.0 (87.5-101.3) 83.0 (78.3-88.0)‡ 84.0 (79.8-86.8)‡
PP (mmHg) 60.0 (54.3-65.0) 48.0 (45.5-52.3)‡ 54.0 (47.8-61.3)§
CAD group (n = 20)
SBP (mmHg) 153.5 (139.5-163.5)† 134.5 (123.0-148.0)†‡ 134.0 (125.5-147.0)†‡
DBP (mmHg) 84.5 (78.0-93.0)† 80.5 (70.5-84.5)† 75.5 (69.5-85.0)†‡
MABP (mmHg) 102.0 (95.5-113.0)† 96.5 (88.5-104.0)† 94.0 (85.0-99.0)†‡
PP (mmHg) 64.0 (60.0-72.0) 50.5 (46.5-66.5)‡ 57.0 (53.0-64.0)‡
*Values presented are medians (25-75 percentile).
†P < .05 between controls and patients with CAD.
‡P < .05 vs before FR.
§P < .05 vs 30 min after FR.
Abbreviations: CAD, coronary artery disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; MABP, mean arterial blood pressure; PP, pulse pressure.
TABLE 3 Percentage Changes in Blood Pressure After
Foot Reexology*
%X30 %X60
Control group (n = 17)
SBP; %
DBP; %
MABP; %
PP; %
CAD group (n = 20)
SBP; %
DBP; %
MABP; %
PP; %
–15.2 (–18.5 to –8.3)
–5.5 (–8.2 to –3.7)
–11.0 (–16.8 to –6.9)
–15.9 (–26.7 to –10.8)
–10.2 (–14.6 to –3.8)
–8.1 (–12.4 to 0.0)
–5.6 (–14.0 to –0.1)
–13.5 (–23.7 to –5.3)
–8.3 (–12.5 to –2.8)†
–8.1 (–14.3 to –4.1)
–9.3 (–16.7 to –3.8)
–8.5 (–16.1 to –1.2)†
–6.6 (–14.1 to –3.1)
–8.1 (–9.7 to –4.4)
–7.3 (–12.5 to –4.1)
–9.1 (–16.7 to 1.7)†
*Values presented are medians (25-75 percentile).
†P < .05 vs %X30.
Abbreviations: CAD, coronary artery disease; SBP, systolic blood pressure;
DBP, diastolic blood pressure; MABP, mean arterial blood pressure; PP,
pulse pressure.

12 ALTERNATIVE THERAPIES, jul/aug 2011, VOL. 17, NO. 4 Foot Reexology in Coronary Ar tery Disease
but this study showed that foot reexology can also increase vagal
modulation.
Reexology is the study of working on the specic reex points
(areas) on the hands, feet, and ears that mirror the whole body in
order to relax and relieve stress and pain.23-26 In clinical terms, reex-
ology is the application of pressure, primarily but not limited to the
feet, hands, or ears, that causes a physiological response in the body.
Many studies have examined the efcacy of reexology. However,
controversy existed regarding efficacy of reflexology.27,56-60 Frankel
found that the frequency of sinus arrhythmia after reexology and
FM was increased by 43.9% and 34.1%, respectively; he suggested a
“neuro theory” whereby reflexology and foot massage alter the
baroreceptor reex sensitivity by stimulating the sensory nervous
system in the feet.56 Hattan et al have investigated the impact of foot
massage and guided relaxation on the well-being of patients who had
undergone coronary artery bypass graft surgery and demonstrated
that these interventions appear to be effective noninvasive tech-
niques for promoting psychological well-being in this patient group.57
Some studies have pointed out that reexology possesses the poten-
tial to provide relief of pain and symptoms and induce
relaxation.25,58,59 Hayes and Cox60 also demonstrated that a 5-minute
foot massage had the potential effect of increasing relaxation as evi-
denced by a signicant decrease in heart rate, blood pressure, and
respiration during the brief foot massage intervention administered
to critically ill patients in intensive care.
In this study, we found that FR results in positive effects on
blood pressure and autonomic nervous modulation in both control
group and patients with CAD. The nHFP was signicantly increased
after FR, whereas the nVLFP and LFP/HFP were significantly
decreased after FR, in both control and CAD groups. This result sug-
gested that a higher vagal modulation, lower sympathetic modula-
tion, renin-angiotensin modulations and thermoregulatory activity
can be observed following 60 minutes of FR in both angiographically
patent controls and CAD patients. However, the increase in mean
RRI, SDRR, TP, VLFP, LFP, and HFP in the CAD group 60 minutes
after FR was still present, whereas these measures were decreased in
the control group 60 minutes after FR (Table 4). It seems that the ben-
ecial effect of FR on HRV measures, especially on those measures
TABLE 4 Effect of Foot Reexology (FR) on Heart Rate Variability Measures (HRV)*
Before FR 30 Min After FR 60 Min After FR
Control group (n = 17)
Mean RRI (ms) 861.9 (781.3-948.7) 839.5 (776.0-981.0) 827.0 (765.7-921.6)
Heart rate (bpm) 69.6 (63.2-76.8) 71.5 (61.2-77.3) 72.6 (65.1-78.4)
SDRR (ms) 52.3 (48.5-60.3) 48.1 (45.6-57.7) 44.8 (42.3-49.5)
CVRR (%) 6.0 (5.4-6.6) 5.9 (5.4-6.4) 5.4 (5.3-6.0)
TP (ms2) 946 (784-1428) 808 (642-1242) 640 (552-866)‡§
VLFP (ms2) 312 (186-497) 226 (135-385)‡ 135 (106-179)‡§
LFP (ms2) 251 (172-406) 206 (152-390) 188 (153-276)
HFP (ms2) 369 (311-547) 390 (286-532) 344 (268-428)
nVLFP (nu) 33.1 (28.4-41.9) 27.8 (19.0-33.8)‡ 20.2 (14.5-26.1)‡
nLFP (nu) 28.3 (20.5-29.4) 26.9 (23.7-29.0) 29.0 (25.6-32.5)
nHFP (nu) 38.6 (33.4-46.2) 47.2 (40.9-55.0)‡ 50.7 (43.7-54.5)‡§
LFP/HFP 0.71 (0.53-0.82) 0.61 (0.51-0.66) 0.59 (0.49-0.67)
CAD group (n = 20)
Mean RRI (ms) 831.1 (762.3-903.0) 917.5 (849.7-928.6)‡ 911.0 (861.6-922.4)‡
Heart rate (bpm) 72.2 (66.5-78.7) 65.4 (64.6-70.6)‡ 65.9 (65.1-69.6)‡
SDRR (ms) 52.6 (45.2-62.5) 53.5 (49.4-66.6) 55.2 (49.6-60.7)†
CVRR (%) 6.3 (5.5-7.2) 6.0 (5.5-7.1) 5.8 (5.4-6.5)
TP (ms2) 981 (694-1526) 979 (886-1630) 1134 (931-1499)†
VLFP (ms2) 257 (174-545) 233 (163-398) 212 (153-346)†
LFP (ms2) 271 (208-491) 293 (278-407) 322 (259-449)†
HFP (ms2) 470 (277-555) 515 (413-648) 527 (457-732)†
nVLFP (nu) 30.6 (24.9-32.9) 23.5 (17.7-29.0)‡ 20.0 (14.2-29.0)‡
nLFP (nu) 28.4 (25.8-31.5) 29.2 (28.1-31.7) 29.5 (27.4-30.7)
nHFP (nu) 42.8 (34.8-46.3) 46.4 (40.9-50.9)‡ 52.1 (42.9-55.4)‡
LFP/HFP 0.66 (0.53-0.83) 0.62 (0.52-0.77) 0.57 (0.52-0.66)
*Values presented are medians (25-75 percentile).
†P < .05 between normal controls and patients with CAD.
‡P < .05 vs before FR.
§P < .05 vs 30 min after FR.
Abbreviations: CAD, coronary artery disease; RRI, RR intervals; SDRR, standard deviation of RR; CVRR, coefcient of variation of RR; TP, total power; VLFP, very
low-frequency power; LFP, low-frequency power; HFP, high-frequency power; nVLFP, normalized very low-frequency power; nLFP, normalized low-frequency power;
nHFP, normalized high-frequency power; LFP/HFP, low-/high-frequency power ratio.

ALTERNATIVE THERAPIES, jul/aug 2011, VOL. 17, NO. 4 13
Foot Reexology in Coronary Artery Disease
related to vagal modulation, last longer in patients with CAD than in
the controls. The mechanism responsible for this differential effect
was not clear at present because it was not investigated in this study.
We speculate that the FR-related autonomic nervous effect of increas-
ing vagal and decreasing sympathovagal balance may be more evi-
dent in those patients who have depressed vagal modulation and
enhanced sympathetic modulation, such as patients with CAD.
Further studies are needed to disclose the underlying mechanism.
Other considerations include that the manipulation of FR on a
participant did not allow him or her to rest uninterruptedly. Thus, a
participant not receiving FR is not a good control to contrast the
effect of FR on that person. If a control is going to be used to contrast
the effect of FR, manipulating some area other than the foot that has
no reex points on it for the same period of time may be a better
choice than a participant not receiving FR. According to the tradi-
tional Oriental medicine, no area over the whole body can be found
that can be stimulated by pressure and massage without causing a
physiological response in the body. Therefore, the participant not
receiving FR in either group was not designed as a control to contrast
the effect of FR in this study.
To know the differences in the effects of FR on patients who are
on different medications and the effects of those medications on FR,
we chose to compare the effect of beta-blockers on the HRV mea-
sures in both control and CAD groups. We found that there were no
signicant differences in all HRV measures between participants
using or not using beta-blockers in either control or CAD group and
between the control and CAD groups whether they were using beta-
blockers or not (Table 6). Thus, there are no differences in the effects
of FR on CAD patients whether or not they are on beta-blocker medi-
cation, and the beta-blockers do not signicantly inuence the effect
of FR on the autonomic nervous modulation of the participants.
In conclusion, a higher vagal modulation, lower sympathetic
modulation, and lower blood pressures can be observed following 60
minutes of FR in both angiographically patent controls and CAD
patients. Though the magnitude of change in the autonomic nervous
modulation of the CAD patients was slightly smaller than that of the
controls, FR is a complementary therapeutic method to allopathic
medical care that is simple and safe for almost everyone. FR requires
very little time and expense, no special equipment, and no medica-
tion and can be performed practically anywhere. Since the mortality
risk due to acute myocardial infarction is lower in patients with higher
vagal modulation and is higher in patients with higher sympathetic
modulation, our research suggests that FR is a safe, low-cost adjunct
TABLE 5 The Percentage Changes in Heart Rate Variability
Measures After Foot Reexology*
%X30 %X60
Control group (n = 17)
Mean RRI; % –0.6 (–4.0 to 4.8)‡ –4.2 (–9.1 to 0.9)
Heart rate; % 0.6 (–4.6 to 4.0)‡ 4.3 (–0.8 to 10.0)‡
SDRR; % 0.0 (–10.4 to 6.5) –13.3 (–17.6 to –1.2)‡
CVRR; % –0.5 (–8.7 to 8.1) –4.6 (–12.5 to 1.1)
TP; % –5.7 (–21.9 to 18.4) –28.0 (–36.0 to –8.4)‡
VLFP; % -12.2 (–38.6 to 3.6) –56.0 (–69.8 to –33.9)‡
LFP; % 0.0 (–15.7 to 19.1) –23.2 (–39.6 to 13.3)‡
HFP; % 3.6 (–9.1 to 30.2) –6.9 (–30.0 to 13.0)
nVLFP; % –9.3 (–42.5 to 1.1) –37.3 (–49.6 to –26.5)
nLFP; % 1.0 (–9.2 to 24.7) 14.1 (–2.9 to 23.5)
nHFP; % 9.9 (–0.0 to 41.3) 18.0 (7.8 to 52.0)
LFP/HFP; % –14.3 (–28.5 to 16.6) –5.7 (–23.2 to 7.9)
CAD group (n = 20)
Mean RRI; % 6.6 (3.1 to 11.1)† 10.9 (3.5 to 17.7)†
Heart rate; % –6.2 (–10.0 to –3.1)† –9.9 (–15.0 to –3.4)†
SDRR; % 4.3 (–8.7 to 23.7) 3.8 (–6.6 to 11.0)†
CVRR; % 0.0 (–12.8 to 12.4) –6.0 (–10.4 to –2.0)
TP; % 11.3 (–25.1 to 58.9) 14.5 (–13.3 to 38.5)†
VLFP; % –0.3 (–39.9 to 21.6) –14.5 (–40.6 to 10.3)†
LFP; % 7.6 (–22.3 to 72.8) 13.8 (–6.7 to 40.7)†
HFP; % 10.0 (–13.2 to 53.3) 32.4 (6.0 to 59.2)†
nVLFP; % –16.4 (–28.2 to –2.9) –18.4 (–40.6 to –4.5)
nLFP; % 0.5 (–6.7 to 7.1) 2.0 (–5.1 to 11.7)†
nHFP; % 8.9 (0.0 to 25.9) 15.1 (1.3 to 33.1)
LFP/HFP; % –11.2 (–23.3 to 2.1) –9.1 (–31.5 to 3.7)
*Values presented are medians (25-75 percentile).
†P < .05 between normal controls and patients with CAD.
‡P < .05 vs before FR.
§P < .05 vs 30 min after FR.
Abbreviations: CAD, coronary artery disease; RRI, RR intervals; SDRR, stan-
dard deviation of RR; CVRR, coefcient of variation of RR; TP, total power;
VLFP, very low-frequency power; LFP, low-frequency power; HFP, high-fre-
quency power; nVLFP, normalized very low-frequency power; nLFP, normal-
ized low-frequency power; nHFP, normalized high-frequency power; LFP/HFP,
low-/high-frequency power ratio.
TABLE 6 Effect of Beta-blockers on Heart Rate Variability in the
Control and Coronary Artery Disease (CAD) Groups*
Control Group (n = 17) CAD Group (n = 20)
Without beta-blockers (n = 12)
TP (ms2) 861.6 (696.0-9876.9) 1415.0 (467.0-2036.0)
VLFP (ms2) 312.0 (176.2-406.9) 218.0 (165.3-733.0)
LFP (ms2) 174.5 (158.5-255.1) 382.0 (127.7-641.2)
HFP (ms2) 373.3 (228.2-493.5) 460.5 (194.4-927.8)
nVLFP (nu) 36.0 (24.3-41.9) 31.2 (26.2-37.7)
nLFP (nu) 23.8 (20.2-29.2) 28.2 (26.4-31.3)
nHFP (nu) 42.9 (35.4-48.1) 37.7 (33.2-48.6)
LFP/HFP 0.53 (0.48-0.81) 0.82 (0.52-0.90)
With beta-blockers (n = 25)
TP (ms2) 1083.1 (827.2-2104.0) 962.5 (7484.1-1375.0)
VLFP (ms2) 311.9 (197.5-514.1) 288.4 (173.8-444.4)
LFP (ms2) 337.1 (177.9-413.1) 256.8 (219.4-437.9)
HFP (ms2) 354.1 (318.7-625.3) 480.2 (318.4-546.6)
nVLFP (nu) 33.0 (30.3-41.3) 30.5 (24.1-32.7)
nLFP (nu) 28.3 (21.5-30.1) 28.6 (25.2-32.4)
nHFP (nu) 38.5 (32.6-44.0) 43.2 (35.5-46.2)
LFP/HFP 0.74 (0.59-0.81) 0.65 (0.53-0.82)
*Values presented are medians (25-75 percentile).
Abbreviations: TP, total power; VLFP, very low-frequency power; LFP, low-
frequency power; HFP, high-frequency power; nVLFP, normalized very low-
frequency power; nLFP, normalized low-frequency power; nHFP, normalized
high-frequency power; LFP/HFP, low-/high-frequency power ratio.

14 ALTERNATIVE THERAPIES, jul/aug 2011, VOL. 17, NO. 4 Foot Reexology in Coronary Artery Disease
treatment that can be used as an effective physiological vagal enhanc-
er and sympathetic suppressor in both control and CAD patients to
benet cardiovascular health.
Acknowledgments
This study was supported by the project VGHUST93-P1-08 of the Joint Research Program of
Veterans General Hospital and University System, Taiwan, and the project CCMP97-RD047 of the
Committee on Chinese Medicine and Pharmacy, Department of Health, Taipei, Taiwan.
REFERENCES
1. Ferrari AU, Radaelli A, Centola M. Invited review: aging and the cardiovascular system. J
Appl Physiol. 2003;95(6):2591-2597.
2. Seals DR, Esler MD. Human ageing and the sympathoadrenal system. J Physiol.
2000;528(Pt 3):407-417.
3. Lipsitz LA, Mietus J, Moody GB, Goldberger AL. Spectral characteristics of heart rate vari-
ability before and during postural tilt. Relations to aging and risk of syncope. Circulation.
1990;81(6):1803-1810.
4. Lombardi F, Sandrone G, Pernpruner S, et al. Heart rate variability as an index of sympathova-
gal interaction after acute myocardial infarction. Am J Cardiol. 1987;60(16):1239-1245.
5. Lishner M, Akselrod S, Avi VM, Oz O, Divon M, Ravid M. Spectral analysis of heart rate
uctuations. A non-invasive, sensitive method for the early diagnosis of autonomic neu-
ropathy in diabetes mellitus. J Auton Nerv Syst. 1987;19(2):119-125.
6. Axelrod S, Lishner M, Oz O, Bernheim J, Ravid M. Spectral analysis of uctuations in heart
rate: an objective evaluation of autonomic nervous control in chronic renal failure.
Nephron. 1987;45(3):202-206.
7. Saul JP, Arai Y, Berger RD, Lilly LS, Colucci WS, Cohen RJ. Assessment of autonomic regu-
lation in chronic congestive heart failure by hear t rate spectral analysis. Am J Cardiol.
1988;61(15):1292-1299.
8. Ryan C, Hollenberg M, Harvey DB, Gwynn R. Impaired parasympathetic responses in
patients after myocardial infarction. Am J Cardiol. 1976;37(7):1013-1018.
9. Tristani FE, Kamper DG, McDermott DJ, Peters BJ, Smith JJ. Alternations of postural and
Valsalva responses in coronary heart disease. Am J Physiol. 1977;233(6):H694-H699.
10. Bennett T, Wilcox RG, Hampton JR. Cardiovascular reexes in patients after myocardial
infarction. Effect of long-term treatment with beta-adrenoceptor antagonists. Br Heart J.
1980;44(3):265-270.
11. Airaksinen KE, Ikäheimo MJ, Linnaluoto MK, Niemelä M, Takkunen JT. Impaired vagal
heart rate control in coronary artery disease. Br Heart J. 1987;58(6):592-597.
12. Hayano J, Sakakibara Y, Yamada M, et al. Decreased magnitude of heart rate spectral com-
ponents in coronary ar tery disease. Its relation to angiographic severity. Circulation.
1990;81(4):1217-1224.
13. Kent KM, Smith ER, Redwood DR, Epstein SE. Electrical stability of acutely ischemic myo-
cardium. Inuences of heart rate and vagal stimulation. Circulation. 1973;47(2):291-298.
14. Vanoli E, De Ferrari GM, Stramba-Badiale M, Hull SS Jr, Foreman RD, Schwartz PJ. Vagal
stimulation and prevention of sudden death in conscious dogs with a healed myocardial
infarction. Cir Res. 1991;68(5):1471-1481.
15. Waxman MB, Wald RW. Termination of ventricular tachycardia by an increase in cardiac
vagal drive. Circulation. 1977;56(3):385-391.
16. Casadei B, Pipilis A, Sessa F, Conway J, Sleight P. Low doses of scopolamine increase cardi-
ac vagal tone in the acute phase of myocardial infarction. Circulation. 1993;88(2);353-357.
17. Pedretti R, Colombo E, Sarzi Braga S, Carù B. Inuence of transdermal scopolamine on
cardiac sympathovagal interaction after acute myocardial infarction. Am J Cardiol.
1993;72(5):384-392.
18. Vybiral T, Glaeser DH, Morris G, et al. Effects of low dose transdermal scopolamine on heart
rate variability in acute myocardial infarction. J Am Coll Cardiol. 1993;22(5):1320-1326.
19. De Ferrari GM, Mantica M, Vanoli E, Hull SS Jr, Schwartz PJ. Scopolamine increases vagal
tone and vagal reflexes in patients after myocardial infarction. J Am Coll Cardiol.
1993;22(5):1327-1334.
20. La Rovere MT, Mor tara A, Pantaleo P, Maestri R, Cobelli F, Tavazzi L. Scopolamine
improves autonomic balance in advanced congestive heart failure. Circulation.
1994;90(2):838-843.
21. Sneddon JF, Bashir Y, Ward DE. Vagal stimulation after myocardial infarction: accentuat-
ing the positive. J Am Coll Cardiol. 1993;22(5):1335-1337.
22. Gammack JK, Morley JE. Anti-aging medicine—the good, the bad, and the ugly. Clin
Geriatr Med. 2004;20(2):157-177.
23. Carter M, Weber T. Body Reexology: Healing at Your Fingertips. New York, NY: Parker
Publishing Co; 1994.
24. Palma RP. Hand and Foot Reexology: Do It Yourself Treatment and Rejuvenation. Concepcion,
Tarlac: R.P. Palma, 1986.
25. Chia M. Chi Self-Massage: The Taoist Way of Rejuvenation. New York, NY: Healing Tao
Books; 1986.
26. Weber KK. Healing Self-Massage: Over 100 Simple Techniques for Re-energizing Body and
Mind. New York, NY: Sterling Publishing; 2005.
27. Wang MY, Tsai PS, Lee PH, Chang WY, Yang CM. The efcacy of reexology: systematic
review. J Adv Nurs. 2008;62(5):512-520.
28. Sudmeier I, Bodner G, Egger I, Mur E, Ulmer H, Herold M. Changes of renal blood ow
during organ-associated foot reexology measured by color Doppler sonography [article
in German]. Forsch Komplementarmed. 1999;6(3):129-134.
29. Stephenson N, Dalton JA, Carlson J. The effect of foot reexology on pain in patients with
metastatic cancer. Appl Nurs Res. 2003;16(4):284-286.
30. Stephenson NL, Weinrich SP, Tavakoli AS. The effects of foot reexology on anxiety and
pain in patients with breast and lung cancer. Oncol Nurs Forum. 2000;27(1):67-72.
31. Ballentine K. Ergonomic ped-hydro cavity agitation for therapeutic assistance and relax-
ation use. US patent 2006/0149318 A1.
32. Dishman RK, Nakamura Y, Garcia ME, Thompson RW, Dunn AL, Blair SN. Heart rate
variability, trait anxiety, and perceived stress among physically t men and women. Int J
Psychophysiol. 2000;37(2):121-133.
33. Thompson JJ, Elsenbruch S, Harnish MJ, Orr WC. Autonomic functioning during REM
sleep differentiates IBS symptom subgroups. Am J Gastroenterol. 2002;97(12):3147-3153.
34. Austen WG, Edwards JE, Frye RL, et al. A reporting system on patients evaluated for coro-
nary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery
Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation.
1975;51(4 Suppl):5-40.
35. Chobanian AV, Bakris GL, Black HR, et al; Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and
Blood Institute; National High Blood Pressure Education Program Coordinating
Committee. Seventh report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252.
36. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation,
and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third
Report of National Cholesterol Education Program (NCER) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in adults (Adult Treatment Panel III)
nal report. Circulation. 2002;106(25):3143-3421
37. J Eugster, Cheng EYC. Father Josef’s New Foot Reexology. Taipei, Taiwan: Cosmax Publishing,
2007:136-145.
38. Botting D. Review of literature on the effectiveness of reexology. Complement Ther Nurs
Midwifery. 1997;3(5):123-130.
39. Enzer S. Reexology: A Tool for Midwives. Sydney, Australia: S Enzer; 2000.
40. Hulme J, Waterman H, Hillier VF. The effect of foot massage on patients’ perception of care
following laparoscopic sterilization as day case patients. J Adv Nurs. 1999;30(2):460-468.
41. No authors listed. Heart rate variability: standards of measurement, physiological interpre-
tation, and clinical use. Task Force of the European Society of Cardiology and the North
American Society of Pacing and Electrophysiology. Circulation. 1996;93(5):1043-1065.
42. Taylor JA, Carr DL, Myers CW, Eckberg DL. Mechanisms underlying very-low-frequency
RR-interval oscillations in humans. Circulation. 1998;98(6):547-555.
43. Thayer JF, Nabors-Oberg R, Sollers JJ 3rd. Thermoregulation and cardiac variability: a
time-frequency analysis. Biomed Sci Instrum. 1997;34:252-256.
44. Fleisher LA, Frank SM, Sessler DI, Cheng C, Matsukawa T, Vannier CA. Thermoregulation
and heart rate variability. Clin Sci (Lond). 1996;90(2):97-103.
45. Koizumi K, Terui N, Kollai M. Effect of cardiac vagal and sympathetic nerve activity on
heart rate in rhythmic uctuations. J Auton Nerv Syst. 1985;12(2-3):251-259.
46. Pagani M, Lombardi F, Guzzetti S, et al. Power spectral analysis of heart rate and arterial
pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog.
Circ Res. 1986;59(2):178-193.
47. Ludwig FC. Senescence. Pathology facing medicine’s ultimate issue. Arch Pathol Lab Med.
1981;105(9):445-451.
48. Bonnemeier H, Richardt G, Potratz J, et al. Circadian prole of cardiac autonomic nervous
modulation in healthy subjects: differing effects of aging and gender on heart rate variabili-
ty. J Cardiovasc Electrophysiol. 2003;14(8):791-799.
49. Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ. Decreased heart rate variability and its associa-
tion with increased mortality after acute myocardial infarction. Am J Cardiol.
1987;59(4):256-262.
50. La Rovere MT, Specchia G, Mortara A, Schwartz PJ. Baroreex sensitivity, clinical corre-
lates, and cardiovascular mortality among patients with a rst myocardial infarction: a
prospective study. Circulation. 1988;78(4):816-824.
51. Farrell TG, Paul V, Cripps TR, et al. Baroreex sensitivity and electrophysiological corre-
lates in patients after acute myocardial infarction. Circulation. 1991;83(3):945-952.
52. Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac
death. Experimental basis and clinical observations of post-myocardial risk stratication.
Circulation. 1992;85(1Suppl):I77-I91.
53. Goldsmith RL, Bigger JT Jr, Steinman RC, Fleiss JL. Comparison of 24-hour parasympa-
thetic activity in endurance-trained and untrained young men. J Am Coll Cardiol.
1992;20(3):552-558.
54. Dibner-Dunlap ME, Eckberg DL, Magid NM, Cintrón-Treviño NM. The long-term
increase of baseline and reexly augmented levels of human vagal-cardiac nervous activity
induced by scopolamine. Circulation. 1985;71(4):797-804.
55. Vybiral T, Bryg RJ, Maddens ME, et al. Effects of transdermal scopolamine on heart rate
variability in normal subjects. Am J Cardiol. 1990;65(9):604-608.
56. Frankel BS. The effect of reexology on baroreceptor reex sensitivity, blood pressure and
sinus arrhythmia. Complement Ther Med. 1997;5(2):80-84.
57. Hattan J, King L, Grifths P. The impact of foot massage and guided relaxation following
cardiac surgery: a randomized controlled trial. J Adv Nurs. 2002;37(2):199-207.
58. Degan M, Fabris F, Vanin F, et al. The effectiveness of foot reexotherapy on chronic pain
associated with a herniated disk [article in Italian]. Prof Inferm. 2000;53(2):80-87.
59. Oleson T, Focco W. Randomized controlled study of premenstrual symptoms treated with
ear, hand, and foot reexology. Obstet Gyn. 1993;82(6):906-911.
60. Hayes J, Cox C. Immediate effects of a ve-minute foot massage on patients in critical care.
Intensive Crit Care Nurs. 1999;15(2):77-82.
Pharmaceutical grade dietary supplement
Major component of articular joint cartilage
Nutrients that promote healthy cartilage
HOW DOES AGING AFFECT
COLLAGEN IN THE BODY?
a) As we age, the body’s ability
to make collagen protein slows
down, so there is insufficient new
collagen to make skin, joints and
other parts of the body.
b) Collagen fibers lose their
moist texture and become rigid.
Much of this damage is caused by
free radicals, which are unstable
molecules created when the body
uses oxygen.
WHAT IS COLLAGEN TYPE II?
Collagen Type II is a pharmaceutical
grade dietary supplement that
provides essential nutrients nec-
essary for healthy joint cartilage.
The formula matrix contains vital
components of synovial fluid that
the body requires to make joint
cartilage, including 65-70% col-
lagen type II protein and 25-30%
glycosaminoglycans (GAGs) or
mucopolysaccharides (chondroitin,
glucosamine, & hyaluronic acid).